Kevin Boyle, Alaunos Therapeutics CEO
January 27, 2022 10:30 AM EST
Pharma

Zio­pharm re­brands to Alaunos, clos­es Boston of­fice with new CEO at the reins

Max Gelman

Senior Editor

A lit­tle over a year af­ter fac­ing an ac­tivist at­tack that saw for­mer CEO Lau­rence Coop­er sur­vive but re­tire a few months lat­er, Zio­pharm On­col­o­gy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times